Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer

被引：47

作者：

Feng, Wan ^{[1
,2
]}

Zhang, Bin ^{[1
]}

Cai, Dawei ^{[2
]}

Zou, Xiaoping ^{[1
]}

机构：

[1] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Gastroenterol, Nanjing 210008, Jiangsu, Peoples R China

[2] Nanjing Univ, Sch Med, Nanjing 210008, Jiangsu, Peoples R China

来源：

CANCER LETTERS | 2014年 / 347卷 / 02期

关键词：

Histone deacetylases; HDAC inhibitors; Pancreatic cancer; Combination therapy; SUBEROYLANILIDE HYDROXAMIC ACID; TARGETING TUMOR ANGIOGENESIS; PHASE-III TRIAL; TRICHOSTATIN-A; MESENCHYMAL TRANSITION; EXPRESSION PROFILE; INDUCED APOPTOSIS; CELL-DEATH; IN-VITRO; GEMCITABINE;

D O I：

10.1016/j.canlet.2014.02.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer is a devastating disease with a dismal prognosis. Surgical resection is the only curative option but is heavily hampered by delayed diagnosis. Due to few therapeutic treatments available, novel and efficacious therapy is urgently needed. Histone deacetylase inhibitors (HDACIs) are emerging as a prominent class of therapeutic agents for pancreatic cancer and have exhibited significant anticancer potential with negligible toxicity in preclinical studies. Clinical evaluations of HDACIs are currently underway. HDACIs as monotherapy in solid tumors have proven less effective than hematological malignancies, the combination of HDACIs with other anticancer agents have been assessed for advanced pancreatic cancer. In this review, we describe the molecular mechanism underpin the anticancer effect of HDACIs in pancreatic cancer and summarize the recent advances in the rationale for the combination strategies incorporating HDACIs. In addition, we discuss the importance of identifying predictors of response to HDACI-based therapy. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：183 / 190

页数：8

共 109 条

[1] Histone deacetylase inhibitors: A new perspective for the treatment of leukemia [J].

Abujamra, Ana Lucia ;

dos Santos, Michel Pinheiro ;

Roesler, Rafael ;

Schwartsmann, Gilberto ;

Brunetto, Algemir Lunardi .

LEUKEMIA RESEARCH, 2010, 34 (06) :687-695

[2] Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer [J].

Aghdassi, Ali ;

Sendler, Matthias ;

Guenther, Annett ;

Mayerle, Julia ;

Behn, Claas-Olsen ;

Heidecke, Claus-Dieter ;

Friess, Helmut ;

Buechler, Markus ;

Evert, Matthias ;

Lerch, Markus M. ;

Weiss, Frank Ulrich .

GUT, 2012, 61 (03) :439-448

[3] Targeting apoptosis pathways in pancreatic cancer [J].

Arlt, Alexander ;

Mueerkoester, Susanne Sebens ;

Schaefer, Heiner .

CANCER LETTERS, 2013, 332 (02) :346-358

[4] Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer [J].

Arumugam, Thiruvengadam ;

Ramachandran, Vijaya ;

Fournier, Keith F. ;

Wang, Huamin ;

Marquis, Lauren ;

Abbruzzese, James L. ;

Gallick, Gary E. ;

Logsdon, Craig D. ;

McConkey, David J. ;

Choi, Woonyoung .

CANCER RESEARCH, 2009, 69 (14) :5820-5828

[5] Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells [J].

Bai, Jirong ;

Demirjian, Aram ;

Sui, Jianhua ;

Marasco, Wayne ;

Callery, Mark P. .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 348 (04) :1245-1253

[6] The mammalian epigenome [J].

Bernstein, Bradley E. ;

Meissner, Alexander ;

Lander, Eric S. .

CELL, 2007, 128 (04) :669-681

[7] Anticancer activities of histone deacetylase inhibitors [J].

Bolden, Jessica E. ;

Peart, Melissa J. ;

Johnstone, Ricky W. .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784

[8] Rational Combinations Using HDAC Inhibitors [J].

Bots, Michael ;

Johnstone, Ricky W. .

CLINICAL CANCER RESEARCH, 2009, 15 (12) :3970-3977

[9] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[10] Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy [J].

Carew, Jennifer S. ;

Giles, Francis J. ;

Nawrocki, Steffan T. .

CANCER LETTERS, 2008, 269 (01) :7-17

← 1 2 3 4 5 6 7 8 9 10 →